Fiber and Biopolymer Research Institute (FBRI), Texas Tech University, Lubbock, Texas 79409, United States.
525 Solutions, Inc., P.O. Box 2206, Tuscaloosa, Alabama 35403, United States.
Chem Rev. 2023 Oct 25;123(20):11894-11953. doi: 10.1021/acs.chemrev.3c00384. Epub 2023 Oct 5.
This Review aims to summarize advances over the last 15 years in the development of active pharmaceutical ingredient ionic liquids (API-ILs), which make up a prospective game-changing strategy to overcome multiple problems with conventional solid-state drugs, for example, polymorphism. A critical part of the present Review is the collection of API-ILs and deep eutectic solvents (DESs) prepared to date. The Review covers rules for rational design of API-ILs and tools for API-IL formation, syntheses, and characterization. Nomenclature and ionic speciation, and the confusion that these may cause, are highlighted, particularly for speciation in both ILs and DESs of intermediate ionicity. We also highlight and pharmaceutical activity studies, with differences in pharmacokinetic/pharmacodynamic depending on ionicity of API-ILs. A brief overview is provided for the ILs used to deliver drugs, and the Review concludes with key prospects and roadblocks in translating API-ILs into pharmaceutical manufacturing.
本文旨在总结过去 15 年来在活性药物成分离子液体(API-ILs)开发方面的进展,这是克服传统固体药物多方面问题的有前途的变革性策略,例如多晶型现象。本综述的一个关键部分是迄今为止收集的 API-IL 和深共晶溶剂 (DES)。该综述涵盖了 API-IL 合理设计的规则以及 API-IL 形成、合成和表征的工具。突出了命名法和离子形态,以及这些可能引起的混淆,特别是对于中等离子强度的 IL 和 DES 中的形态。我们还重点介绍了 和 药物活性研究,其药代动力学/药效学取决于 API-IL 的离子性。简要概述了用于输送药物的 IL,最后展望了将 API-IL 转化为药物制造的关键前景和障碍。